SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

ADCETRIS

TAK·TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on the market; initial FDA approval was in 2011, with multiple label expansions since. No new market entry is pending.
Why 3/10
ADCETRIS is already approved and commercialized across major territories with no pending PDUFA date or pivotal readout in the next 12 months. It is a meaningful but non-dominant component of Takeda's diversified global portfolio, so even a major label expansion or sales surprise would move Takeda's stock modestly at most.
Actionable Insight NEUTRAL

ADCETRIS is a mature commercial asset with no hard binary catalyst on the near-term calendar. Investors should watch for any new Phase 3 data readouts for label expansion (such as the ongoing S1826 trial comparing it against nivolumab combinations), biosimilar entry timelines as patents begin expiring, and quarterly revenue trends within Takeda's oncology segment reports.

Price Chart

Loading chart...

Executive Summary

ADCETRIS (brentuximab vedotin) is a CD30-directed antibody-drug conjugate first approved by the FDA in 2011 for multiple lymphoma indications. Takeda holds commercialization rights outside the US and Canada under a 2009 partnership with Seagen (now part of Pfizer). The drug is already approved and generating revenue across its territories; Takeda's oncology segment, which includes ADCETRIS alongside ALUNBRIG and NINLARO, contributed roughly ¥580 billion (about 13% of total revenue) in FY2025. The most recent label expansions occurred in 2025: a February 2025 FDA approval in combination with lenalidomide and rituximab for relapsed/refractory large B-cell lymphoma, and a June 2025 European Commission approval of the BrECADD regimen for newly diagnosed advanced Hodgkin lymphoma. For Takeda, ADCETRIS is a meaningful but non-dominant component of a diversified global portfolio, and no new PDUFA or pivotal readout is pending in the next 12 months.

How It Works

ADCETRIS is an antibody-drug conjugate, a kind of targeted cancer therapy. It works like a guided missile: one part of the drug is an antibody that seeks out and binds to a protein called CD30 found on certain lymphoma cells. Once attached, the drug releases a toxic chemotherapy agent directly inside the cancer cell, killing it while largely sparing healthy cells.

Trial Status

ADCETRIS is already approved and commercially available across multiple indications in the US (by Pfizer/Seagen) and ex-US/Canada territories (by Takeda). It has accumulated over a decade of real-world use. Several completed Phase 3 trials (ECHELON-1, ECHELON-2, HD21) support its current approved indications. An ongoing Phase 3 trial (S1826, NCT03907488) is comparing brentuximab vedotin plus AVD against nivolumab plus AVD in newly diagnosed advanced-stage classical Hodgkin lymphoma, with a last update in October 2026 indicating the study is active but no longer recruiting.

The Two-Sided Case

▲ Bull Case4
Multiple approved indications across CD30-positive lymphomas provide a broad and durable revenue base
Recent EU approval of the BrECADD regimen (June 2025) expands the frontline Hodgkin lymphoma market for Takeda's territory
ADCETRIS is part of the growing ADC drug class and has established real-world clinical data and reimbursement across Takeda's markets
Takeda's oncology segment showed 3.5% YoY growth in FY2025, to which ADCETRIS contributes
▼ Bear Case4
US patents for ADCETRIS began expiring in 2024, opening the door to biosimilar competition and eventual revenue erosion
ADCETRIS faces competition from newer, potentially more effective therapies including PD-1 inhibitors like Keytruda (pembrolizumab) and other ADCs
Takeda only controls ex-US/Canada rights, limiting upside compared to a global owner
As an established drug, ADCETRIS has no near-term binary catalyst that could drive significant share-price appreciation for Takeda

Upcoming Catalysts

  • Quarterly revenue updates from Takeda's oncology segment reports
  • Long-term follow-up data from the HD21 and ECHELON-1/2 Phase 3 trials
  • Potential biosimilar entry as patents begin to expire
  • Results from the ongoing Phase 3 S1826 trial comparing ADCETRIS against nivolumab combinations

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 takeda.com3 takedaoncology.com4 accessdata.fda.gov5 koalagains.com6 drugpatentwatch.com7 whobrands.com8 en.wikipedia.org9 drugs.com10 pfizer.com